Literature DB >> 6705425

Pharmacokinetic consequences of drug displacement from blood and tissue proteins.

J J MacKichan.   

Abstract

Displacement of one drug by another from blood and/or tissue protein will alter the pharmacokinetic behaviour of the displaced drug. For restrictively cleared drugs, displacement from blood proteins will cause only a transient change in free drug concentration and hence in pharmacodynamic response, so that dosage adjustments are rarely necessary. Total drug concentrations, however, are decreased and must be appropriately interpreted. Binding displacement from blood and/or tissue will also shorten the half-lives of these drugs, thus magnifying peak-trough differences during a dosage interval. These theoretical expectations are supported by examples of drug displacement interactions involving warfarin and phenytoin. Although total drug concentrations in blood will be unchanged, free drug concentrations will be increased and drug response enhanced for non-restrictively cleared drugs as a result of displacement from blood protein, possibly necessitating a dosage reduction.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6705425     DOI: 10.2165/00003088-198400091-00005

Source DB:  PubMed          Journal:  Clin Pharmacokinet        ISSN: 0312-5963            Impact factor:   6.447


  29 in total

1.  Perfusion-limited of plasma drug binding on hepatic drug extraction.

Authors:  D G Shand; R H Cotham; G R Wilkinson
Journal:  Life Sci       Date:  1976-07-01       Impact factor: 5.037

2.  Liquid-chromatographic assay of diazepam and its major metabolites in plasma.

Authors:  J J MacKichan; W J Jusko; P K Duffner; M E Cohen
Journal:  Clin Chem       Date:  1979-06       Impact factor: 8.327

Review 3.  Factors affecting drug metabolism.

Authors:  J R Gillette
Journal:  Ann N Y Acad Sci       Date:  1971-07-06       Impact factor: 5.691

4.  Enhancement of warfarin-induced hypoprothrombinemia by triclofos.

Authors:  E M Sellers; M Lang; J Koch-Weser; R W Colman
Journal:  Clin Pharmacol Ther       Date:  1972 Nov-Dec       Impact factor: 6.875

5.  Potentiation of warfarin-induced hypoprothrombinemia by chloral hydrate.

Authors:  E M Sellers; J Koch-Weser
Journal:  N Engl J Med       Date:  1970-10-15       Impact factor: 91.245

6.  Effect of plasma protein and tissue binding on the biologic half-life of drugs.

Authors:  M Gibaldi; G Levy; P J McNamara
Journal:  Clin Pharmacol Ther       Date:  1978-07       Impact factor: 6.875

7.  Serum protein binding as a determinant of warfarin body clearance and anticoagulant effect.

Authors:  A Yacobi; J A Udall; G Levy
Journal:  Clin Pharmacol Ther       Date:  1976-05       Impact factor: 6.875

8.  Effects of aspirin on salivary and serum phenytoin kinetics in healthy subjects.

Authors:  J W Paxton
Journal:  Clin Pharmacol Ther       Date:  1980-02       Impact factor: 6.875

9.  Phenytoin-salicylate interaction.

Authors:  R F Leonard; P J Knott; G O Rankin; D S Robinson; D E Melnick
Journal:  Clin Pharmacol Ther       Date:  1981-01       Impact factor: 6.875

10.  Interaction between phenytoin and valproic acid: plasma protein binding and metabolic effects.

Authors:  E Perucca; S Hebdige; G M Frigo; G Gatti; S Lecchini; A Crema
Journal:  Clin Pharmacol Ther       Date:  1980-12       Impact factor: 6.875

View more
  20 in total

Review 1.  Methods of determining plasma and tissue binding of drugs. Pharmacokinetic consequences.

Authors:  G M Pacifici; A Viani
Journal:  Clin Pharmacokinet       Date:  1992-12       Impact factor: 6.447

Review 2.  Protein binding drug displacement interactions fact or fiction?

Authors:  J J MacKichan
Journal:  Clin Pharmacokinet       Date:  1989-02       Impact factor: 6.447

Review 3.  Pharmacokinetic drug interactions with nonsteroidal anti-inflammatory drugs.

Authors:  R K Verbeeck
Journal:  Clin Pharmacokinet       Date:  1990-07       Impact factor: 6.447

4.  Pharmacokinetics of quinidine in male patients. A population analysis.

Authors:  C N Verme; T M Ludden; W A Clementi; S C Harris
Journal:  Clin Pharmacokinet       Date:  1992-06       Impact factor: 6.447

Review 5.  Pharmacokinetics and pharmacodynamics in critically ill patients.

Authors:  H J Mann; D W Fuhs; F B Cerra
Journal:  World J Surg       Date:  1987-04       Impact factor: 3.352

Review 6.  The influence of binding to albumin and alpha 1-acid glycoprotein on the clearance of drugs by the liver.

Authors:  D K Meijer; P Van der Sluijs
Journal:  Pharm Weekbl Sci       Date:  1987-04-24

7.  In vitro protein binding of cefonicid and cefuroxime in adult and neonatal sera.

Authors:  J M Benson; F D Boudinot; A T Pennell; F E Cunningham; J T DiPiro
Journal:  Antimicrob Agents Chemother       Date:  1993-06       Impact factor: 5.191

8.  In vitro protein binding of propafenone in normal and uraemic human sera.

Authors:  G L Chan; J E Axelson; J D Price; K M McErlane; C R Kerr
Journal:  Eur J Clin Pharmacol       Date:  1989       Impact factor: 2.953

9.  Ponalrestat does not cause a protein binding interaction with warfarin in diabetic patients.

Authors:  R F Moulds; R O Fullinfaw; R W Bury; W E Plehwe; N Jacka; K M McGrath; F I Martin
Journal:  Br J Clin Pharmacol       Date:  1991-06       Impact factor: 4.335

10.  Differences between the measured and calculated free serum phenytoin concentrations in epileptic patients.

Authors:  Ji-Man Hong; Young-Chul Choi; Won-Joo Kim
Journal:  Yonsei Med J       Date:  2009-08-19       Impact factor: 2.759

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.